Drug Trial Radar · NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
293
Planned (sponsor's estimate)
Start
Feb 12, 2024
Primary completion
Oct 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Frontier Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate FMC-376 monotherapy and in combination with pembrolizumab in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.
Conditions
- Advanced Solid Tumors With KRAS G12C Mutations
- Solid Tumor, Adult
- Unresectable Solid Tumor
- Metastatic Solid Tumor
- Non Small Cell Lung Cancer
- KRAS G12C
Interventions
FMC-376Drug
Oral Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ph 1a: Dose Limiting ToxicitiesTime frame: Up to 21 Days
- Ph 1a: Adverse Events (AEs)Time frame: Approximately 24 Months
- Ph 1b/Ph2: Overall Response Rate (ORR)Time frame: Approximately 24 Months
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center
La Jolla, California · Recruiting
University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center
Orange, California · Completed
University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Florida Cancer Specialists and Research Institute
Lake Mary, Florida · Completed
Northwest Cancer Centers
Dyer, Indiana · Recruiting
The University of Kansas Cancer Center
Fairway, Kansas · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Community Clinical Trials
Kingwood, Texas · Completed
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas · Recruiting
UT Health San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Completed
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Macquarie University
Macquarie Park, New South Wales, Australia · Recruiting
Tasman Health Care
Southport, Queensland, Australia · Recruiting
Icon Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia · Recruiting
GenesisCare North Adelaide
North Adelaide, South Australia, Australia · Completed
Eastern Health - Box Hill Hospital
Box Hill, Victoria, Australia · Completed
Linear Clinical Research Ltd
Nedlands, Western Australia, Australia · Recruiting
Seoul National University Hospital
Seoul, Jongno-gu, South Korea · Recruiting
Severance Hospital
Seoul, Seodaemun-gu, South Korea · Recruiting
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea · Recruiting
Seoul National University Bundang Hospital
Gyeonggi-do, Seongnam-si, South Korea · Recruiting
The Catholic University of Korea, St. Vincent's Hospital
Gyeonggi-do, Suwon-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.